Bayer accelerates MXN 3 billion investment in Mexico and allocates MXN 150 million to clinical research

Bayer Mexico reported that, during 2026, it will invest MXN 150 million in clinical research through the development of 10 studies involving public and private institutions in the country, while also advancing the MXN 3 billion investment program previously announced for the modernization and expansion of its productive operations.

Daniel Londero, General Manager of Bayer Mexico, explained that the clinical studies include collaboration with institutions such as the National Cancer Institute, the University Hospital of Monterrey, the National Institute of Pediatrics, the Children’s Hospital of Mexico and La Raza General Hospital.

“This year, we will be taking significant steps in clinical research with an investment of MXN 150 million in 10 clinical studies.”

The executive highlighted that one of the factors that made it possible to accelerate these initiatives was the reduction in regulatory approval times by COFEPRIS.

“The reduction in approval times for clinical studies is bringing us closer to international standards, and this improvement not only allows Mexican patients to access innovation, but also strengthens our health infrastructure.”

Bayer promotes clinical research and collaboration with public hospitals

Londero announced that, in July, an observational study will begin in 12 IMSS family medicine units located in eight states across the country, a project to which MXN 15 million will be allocated. According to the executive, this model seeks to strengthen collaboration between the pharmaceutical industry and the public health system.

“It is a clear example of what happens when industry and the public sector manage to work together on a common agenda aimed at strengthening Mexico’s clinical research ecosystem.”

The General Manager also reported that the MXN 3 billion investment plan announced for the 2025-2029 period has progressed by more than 33%, equivalent to more than MXN 1 billion already invested to expand and modernize eight production plants and six research sites in the country.

Bayer modernizes plants in the State of Mexico and Veracruz

Among the projects currently underway, he highlighted the expansion of the Lerma plant in the State of Mexico, which has reached 71% progress and represents an investment of MXN 847 million.

He also mentioned the modernization project for the hormonal medicines and APIs plant in Orizaba, Veracruz, which has progressed by more than 20% and represents an investment of more than MXN 150 million.

“With these investments, we expect to exceed MXN 6 billion in annual exports, while also adequately supplying the local market.”